Educated Patient® Lung Cancer Summit Targeted Treatment Session: August 14, 2021

September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.

Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.

Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.

After a lung cancer diagnosis, one Bronx writer reflects on faith, survivorship and learning that healing isn't a finish line, but a daily journey.

Dr. David DiBardino explains how intratumoral therapy is being studied to deliver treatment directly into tumors and potentially enhance radiation in patients with locally advanced non-small cell lung cancer.